Navarro Pardo I1, Agustín Ferrández MJ2, Santander Lobera C3, Escolano Pueyo A1, Galindo Allugama M1, Abad Sazatornil MR4
1 Farmacéutico Interno Residente
2 Farmacéutico Especialista en Farmacia Hospitalaria. Adjunto
3 Médico Especialista en Oncología Médica. Adjunto
4 Farmacéutico Especialista en Farmacia Hospitalaria. Jefe de Servicio
Hospital Universitario Miguel Servet. Zaragoza (España)
Rev. OFIL 2016, 26;3:185-192
Fecha de recepción: 11/05/2015 – Fecha de aceptación: 28/07/2015
Objective: To assess the effectiveness and safety of cabazitaxel and abiraterone in metastatic castration-resistant prostate cancer (mCRPC) patients after docetaxel treatment, selected according to the Abiraterone/Cabazitaxel protocol used in the Autonomous Community.
Materials and methods: Retrospective observational study of patients who initiated cabazitaxel and abiraterone from January-2011 to May-2014, followed-up period until February-2015. The effectiveness was assessed by the overall survival (OS) and progression-free survival (PFS). To evaluate the safety, the frequency and severity of adverse effects were recorded.
Results: A total of 34 patients were included: 17 received abiraterone, 17 received cabazitaxel, 4 were treated with cabazitaxel and abiraterone sequentially. Median OS and PFS in the cabazitaxel group were 16.90 and 6.50 months, and in the abiraterone group were 16.90 and 5.27 months, respectively. The rate of patients ≥75 years was higher in the abiraterone versus the cabazitaxel group (33.3% versus 5.9%). Subgroup analysis of OS and PFS favored hormonotherapy ≥16 months group to hormonotherapy <16 months group (OS 19.00 versus 10.23 months, p=0.029, PFS 6.03 versus 2.80 months, p=0.007, respectively). The most frequent adverse effects were grade 1-2.
Conclusions: Cabazitaxel and abiraterone have proven to prolong survival in men with mCRPC after docetaxel treatment. This study shows the importance to protocolize the use of these therapies to achieve the maximum benefit.
Key Words: Abiraterone, cabazitaxel, metastatic castration-resistant prostatic cancer, chemotherapy-treated, treatment outcomes, safety.
Download PDF: Efectividad y seguridad de los tratamientos post-docetaxel en cáncer de próstata metastásico resistente a castración